Lactoferrin’s Visceral Fat-Reducing Mechanism Explained

Under a philosophy of putting customer satisfaction first, Lion leverages its wealth of technological capabilities related to life science research to develop products based on solid evidence. Metabolic syndrome is a complex lifestyle-related disease marked by the clustering of abdominal obesity, high blood sugar, high blood pressure, and abnormal blood lipid levels. In Japan, one in two men between the ages of 40 and 74 is at risk for metabolic syndrome. In its research on periodontal disease prevention, Lion found that periodontal disease is related to metabolic abnormalities and discovered that lactoferrin, a substance that suppresses periodontal disease-causing bacteria, also has a visceral fat-reducing effect. By investigating the mechanism behind this effect, Lion found that lactoferrin significantly suppresses the synthesis of fat by in-vitro visceral fat cells. Lactoferrin had previously been thought to have an effect on lipid metabolism, but Lion provided the first clear evidence of this relationship through human clinical trials and experiments using visceral fat cell cultures.

R&D Case Study